title: Etanercept attenuates TNBS-induced experimental colitis: role of TNF-α expression.
abstract: Crohn's disease (CD) is associated with gut barrier dysfunction. Tumour necrosis factor-α (TNF-α) plays an important role into the pathogenesis of several inflammatory diseases because its expression is increased in inflamed mucosa of CD patients. Anti-TNF therapy improves significantly mucosal inflammation. Thus, this study aimed to evaluate the effect of Etanercept (ETC), a tumour necrosis factor alpha (TNF-α) antagonist on the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis. A total of 18 Wistar rats were randomized into four groups, as follows: (1) Sham: sham induced-colitis; (2) TNBS: non-treated induced-colitis; (3) ETC control; (4) ETC-treated induced-colitis. Rats from group 4 presented significant improvement either of macroscopic or of histopathological damage in the distal colon. The gene expression of TNF-α mRNA, decreased significantly in this group compared to the TNBS non-treated group. The treatment with etanercept attenuated the colonic damages and reduced the inflammation caused by TNBS. Taken together, our results suggest that ETC attenuates intestinal colitis induced by TNBS in Wistar rats by TNF-α downregulation.
authors.affiliation: Department of Pathology, Universidade Federal de São Paulo-Escola Paulista de Medicina, UNIFESP, São Paulo, SP, Brazil. a.paiotti@unifesp.br
authors.forename: Ana Paula Ribeiro
authors.initials: AP
authors.lastname: Paiotti
authors.forename: Sender Jankiel
authors.initials: SJ
authors.lastname: Miszputen
authors.forename: Celina Tizuko Fujiyama
authors.initials: CT
authors.lastname: Oshima
authors.forename: Ricardo
authors.initials: R
authors.lastname: Artigiani Neto
authors.forename: Daniel Araki
authors.initials: DA
authors.lastname: Ribeiro
authors.forename: Marcello
authors.initials: M
authors.lastname: Franco
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D003106:Colon / Q000187:drug effects / Q000473:pathology; D000068800:Etanercept; D005786:Gene Expression Regulation / Q000187:drug effects; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D007150:Immunohistochemistry; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013194:Staining and Labeling; D014302:Trinitrobenzenesulfonic Acid; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D007074:Immunoglobulin G; D012333:RNA, Messenger; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D014302:Trinitrobenzenesulfonic Acid; D000068800:Etanercept